Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.55 |
| ▸ | FLT1 | P17948 | 7/20 | 0.55 |
| ▸ | FLT4 | P35916 | 7/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924685 | 0.81 | FLT1 (0.49) | KDRFLT1FLT4IMPDH2ALOX5 | |
| SCHEMBL2345680 | 0.79 | KDR (0.51) | KDRFLT1FLT4TRPV1IMPDH2 | |
| SCHEMBL14134354 | 0.78 | KDR (0.73) | KDRFLT1FLT4IMPDH2ALOX5 | |
| SCHEMBL10066362 | 0.76 | FLT1 (0.51) | KDRFLT1FLT4IMPDH2ALOX5 | |
| SCHEMBL2339289 | 0.75 | FLT1 (0.50) | KDRFLT1FLT4ALDH1A1IMPDH2 | |
| SCHEMBL2341696 | 0.74 | FLT1 (0.52) | KDRFLT1FLT4ALDH1A1IMPDH2 | |
| SCHEMBL14058473 | 0.73 | KDR (0.67) | KDRFLT1FLT4IMPDH2ALOX5 | |
| SCHEMBL29993150 | 0.73 | KDR (0.63) | KDRFLT1FLT4IMPDH2 | |
| SCHEMBL2349193 | 0.72 | FLT1 (0.46) | KDRFLT1FLT4TRPV1IMPDH2 | |
| SCHEMBL2341841 | 0.72 | KDR (0.50) | KDRFLT1FLT4ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080669-B2 | Process for the synthesis of 2-aminoxazole compounds | AB SCIENCE (FR) | 2011-12-20 | — | — | US | disclosed |
| EP-2019822-B1 | A NEW PROCESS FOR THE SYNTHESIS OF 2-AMINOXAZOLE COMPOUNDS | AB SCIENCE (FR) | 2010-09-08 | — | — | EP | disclosed |
| US-20090192317-A1 | PROCESS FOR THE SYNTHESIS OF 2-AMINOXAZOLE COMPOUNDS | AB SCIENCE (FR) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192317-A1 | PROCESS FOR THE SYNTHESIS OF 2-AMINOXAZOLE COMPOUNDS | ABL1, FLT3, ABL2 | KDR 14/4885FLT1 8/4885FLT4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.